CHICAGO -- Combining pembrolizumab (Keytruda) with sacituzumab govitecan (SG, Trodelvy) instead of chemotherapy as first-line ...

Many patients with ER-positive/HER2-negative advanced breast cancer eventually develop resistance to standard first-line ...

With the goal to become a top 3 pharma company in China, Novartis has been busy tapping into the expertise of local ...

Experts discuss the use of artificial intelligence (AI) and patient-centric strategies in oncology clinical trials.

Loomis Sayles, an investment management company, released its “Global Growth Fund” first quarter 2025 investor letter. A copy ...

Pharmaceutical companies are making billions on treatments that can sometimes overpromise and underdeliver for terminal cases ...

New breast cancer drug vepdegestrant shows promising results in increasing survival rates for patients with ESR1 mutations.

She joined Novartis more than 20 years ago and has led several of the company’s oncology businesses over the last six years, including region head of Novartis Oncology Europe.

The company’s strategy for global markets is different from the India market and is not solely based on leveraging ...

CDR-Life today announced the appointment of Pascal Touchon, DVM, MBA, to its Board of Directors. Dr. Touchon brings 40 years of international experience in the biopharmaceutical industry, with ...

It's the second deal involving FAP in the pace of 24 hours, after Lantheus Holdings acquired rights to NTI-1309, a PET oncology imaging agent that targets FAP, from Noria Therapeutics. Novartis ...

Anal cancer is relatively uncommon, accounting for approximately 2.5% of all gastrointestinal cancers. Nonetheless, its ...